Are subjects in treatment trials of panic disorder representative of patients in routine clinical practice? Results from a national sample

Journal of Affective Disorders

Volumn 146, Issue 3, 2013, Pages 383-389

  Hoertel, Nicolas ^a,b   Le Strat, Yann ^a,b,c   De Maricourt, Pierre ^b   Limosin, Frédéric ^b,c,d   Dubertret, Caroline ^a,b,c  

^a HÔPITAL LOUIS MOURIER   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Paris Descartes University   (France)

Author keywords

Clinical trials; Eligibility criteria; Generalizability; National epidemiologic survey on alcohol and related conditions (NESARC); Panic disorder

Indexed keywords

AGORAPHOBIA; ALCOHOL ABUSE; ARTICLE; BIPOLAR DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMMUNITY SAMPLE; DEPRESSION; DRUG ABUSE; DSM-IV; EPIDEMIOLOGICAL DATA; HUMAN; PANIC; PATIENT CARE; PRIORITY JOURNAL;

ADULT; CLINICAL TRIALS AS TOPIC; ELIGIBILITY DETERMINATION; GUIDELINES AS TOPIC; HUMANS; PANIC DISORDER; PATIENT SELECTION; UNITED STATES;

EID: 84875214887     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2012.09.023     Document Type: Article

References (51)

1. M.Z. Azhar Comparison of Fluvoxamine alone, Fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan - implications for management by family doctors Medical Journal of Malaysia 55 2000 402 408
2. D.H. Barlow, J.M. Gorman, M.K. Shear, and S.W. Woods Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial Journal of the American Medical Association 283 2000 2529 2536
3. P. Berger, G. Sachs, M. Amering, A. Holzinger, B. Bankier, and H. Katschnig Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder Journal of Affective Disorders 80 2004 75 78
4. C. Blanco, M. Olfson, R.D. Goodwin, E. Ogburn, M.R. Liebowitz, E.V. Nunes, and D.S. Hasin Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions Journal of Clinical Psychiatry 69 2008 1276 1280
5. C. Blanco, M. Olfson, M. Okuda, E.V. Nunes, S.M. Liu, and D.S. Hasin Generalizability of clinical trials for alcohol dependence to community samples Drug and Alcohol Dependence 98 2008 123 128
6. H. Boter, E.M. Derks, W.W. Fleischhacker, M. Davidson, and R.S. Kahn Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European first episode schizophrenia trial (EUFEST) Journal of Clinical Psychiatry 71 2010 58 65
7. G. Canino, M. Bravo, R. Ramirez, V.E. Febo, M. Rubio-Stipec, R.L. Fernandez, and D. Hasin The Spanish alcohol use disorder and associated disabilities interview schedule (AUDADIS): reliability and concordance with clinical diagnoses in a Hispanic population Journal of Studies on Alcohol and Drugs 60 1999 790 799
8. P. Cohen, and J. Cohen The clinician's illusion Archives of General Psychiatry 41 1984 1178 1182
9. E. de Beurs, A.J. van Balkom, A. Lange, P. Koele, and R. van Dyck Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone The American Journal of Psychiatry 152 1995 683 691
10. D.A. Dzewaltowski, P.A. Estabrooks, L.M. Klesges, S. Bull, and R.E. Glasgow Behavior change intervention research in community settings: how generalizable are the results? Health Promotion International 19 2004 235 245
11. T.J. Fahy, D. O'Rourke, J. Brophy, W. Schazmann, and S. Sciascia The galway study of panic disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial Journal of Affective Disorders 25 1992 63 75
12. G.A. Fava, G. Savron, M. Zielezny, S. Grandi, C. Rafanelli, and S. Conti Overcoming resistance to exposure in panic disorder with agoraphobia Acta Psychiatrica Scandinavica 95 1997 306 312
13. T.A. Furukawa, N. Watanabe, and R. Churchill Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review British Journal of Psychiatry 188 2006 305 312
14. B.N. Gaynes, D. Warden, M.H. Trivedi, S.R. Wisniewski, M. Fava, and A.J. Rush What did STARD teach us? Results from a large-scale, practical, clinical trial for patients with depression Psychiatric Services 60 2009 1439 1445
15. I.M. Goldenberg, K. White, K. Yonkers, J. Reich, M.G. Warshaw, R.M. Goisman, and M.B. Keller The infrequency of pure culture diagnoses among the anxiety disorders Journal of Clinical Psychiatry 57 1996 528 533
16. B.F. Grant, D.A. Dawson, F.S. Stinson, S.P. Chou, M.C. Dufour, and R.P. Pickering The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002 Drug and Alcohol Dependence 74 2004 223 234
17. B.F. Grant, D.A. Dawson, F.S. Stinson, P.S. Chou, W. Kay, and R. Pickering The alcohol use disorder and associated disabilities interview schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample Drug and Alcohol Dependence 71 2003 7 16
18. B.F. Grant, T.C. Harford, D.A. Dawson, P.S. Chou, and R.P. Pickering The alcohol use disorder and associated disabilities interview schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample Drug and Alcohol Dependence 39 1995 37 44
19. M.C. Harter, K.P. Conway, and K.R. Merikangas Associations between anxiety disorders and physical illness European Archives of Psychiatry and Clinical Neuroscience 253 2003 313 320
20. D. Hasin, K.M. Carpenter, S. McCloud, M. Smith, and B.F. Grant The alcohol use disorder and associated disabilities interview schedule (AUDADIS): reliability of alcohol and drug modules in a clinical sample Drug and Alcohol Dependence 44 1997 133 141
21. D.S. Hasin, F.S. Stinson, E. Ogburn, and B.F. Grant Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions Archives of General Psychiatry 64 2007 830 842
22. N. Hoertel, Y. Le Strat, C. Blanco, P. Lavaud, and C. Dubertret Generalizability of clinical trial results for generalized anxiety disorder to community samples Depression and Anxiety 29 2012 614 620
23. K. Humphreys, A.H. Harris, and K.R. Weingardt Subject eligibility criteria can substantially influence the results of alcohol-treatment outcome research Journal of Studies on Alcohol and Drugs 69 2008 757 764
24. K. Humphreys, K.R. Weingardt, and A.H. Harris Influence of subject eligibility criteria on compliance with National Institutes of Health guidelines for inclusion of women, minorities, and children in treatment research Alcoholism: Clinical and Experimental Research 31 2007 988 995
25. K. Humphreys, K.R. Weingardt, D. Horst, A.A. Joshi, and J.W. Finney Prevalence and predictors of research participant eligibility criteria in alcohol treatment outcome studies, 1970-98 Addiction 100 2005 1249 1257
26. D.G. Johnston, I.E. Troyer, S.F. Whitsett, and J.T. Dalby Clomipramine treatment and behaviour therapy with agoraphobic women Canadian Journal of Psychiatry 40 1995 192 199
27. M. Kampman, G.P. Keijsers, C.A. Hoogduin, and G.J. Hendriks A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone Journal of Clinical Psychiatry 63 2002 772 777
28. A.Y. Khan, S.H. Preskorn, and B. Baker Effect of study criteria on recruitment and generalizability of the results Journal of Clinical Psychopharmacology 25 2005 271 275
29. Y. Le Strat, J. Rehm, and B. Le Foll How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey Tobacco Control 20 2011 338 343
30. S. Leucht, S. Heres, J. Hamann, and J.M. Kane Methodological issues in current antipsychotic drug trials Schizophrenia Bulletin 34 2008 275 285
31. B. Loerch, M. Graf-Morgenstern, M. Hautzinger, S. Schlegel, C. Hain, J. Sandmann, and O. Benkert Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia British Journal of Psychiatry 174 1999 205 212
32. I.M. Marks, S. Gray, D. Cohen, R. Hill, D. Mawson, E. Ramm, and R.S. Stern Imipramine and brief therapists-aided exposure in agoraphobics having self-exposure homework Archives of General Psychiatry 40 1983 153 162
33. M.R. Mavissakalian, and S. Guo Predictors of entering a long-term drug treatment study of panic disorder Comprehensive Psychiatry 43 2002 88 94
34. M. Mavissakalian, L. Michelson, and R.S. Dealy Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice British Journal of Psychiatry 143 1983 348 355
35. M. Mavissakalian, and L. Michelson Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine Journal of Clinical Psychiatry 47 1986 117 122
36. H.O. Melberg, and K. Humphreys Ineligibility and refusal to participate in randomised trials of treatments for drug dependence Drug and Alcohol Review 29 2010 193 201
37. S. Oehrberg, P.E. Christiansen, K. Behnke, A.L. Borup, B. Severin, J. Soegaard, H. Calberg, R. Judge, J.K. Ohrstrom, and P.M. Manniche Paroxetine in the treatment of panic disorder. a randomised, double-blind, placebo-controlled study British Journal of Psychiatry 167 1995 374 379
38. M. Okuda, D.S. Hasin, M. Olfson, S.S. Khan, E.V. Nunes, I. Montoya, S.M. Liu, B.F. Grant, and C. Blanco Generalizability of clinical trials for cannabis dependence to community samples Drug and Alcohol Dependence 111 2010 177 181
39. D.M. Sharp, K.G. Power, R.J. Simpson, B.A. Swanson, E. Moodie, J.A. Anstee, and J.J. Ashford Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia Journal of Anxiety Disorders 10 1996 219 242
40. D.V. Sheehan, J. Ballenger, and G. Jacobsen Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms Archives of General Psychiatry 37 1980 51 59
41. P. Spinhoven, E.J. Onstein, R.A. Klinkhamer, and E.A.M. Knoppert-van der Klein Panic management, trazodone and a combination of both in the treatment of panic disorder Clinical Psychology and Psychotherapy 3 1996 86 92
42. M.B. Stein, G. Ron Norton, J.R. Walker, M.J. Chartier, and R. Graham Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study Psychiatry Research 94 2000 191 200
43. M.J. Telch, W.S. Agras, C.B. Taylor, W.T. Roth, and C.C. Gallen Combined pharmacological and behavioral treatment for agoraphobia Behaviour Research and Therapy 23 1985 325 335
44. H. Verdoux, and B. Begaud Pharmaco-epidemiology: what do (and don't) we know about utilisation and impact of psychotropic medications in real-life conditions? British Journal of Psychiatry 185 2004 93 94
45. H.I. Weisberg, V.C. Hayden, and V.P. Pontes Selection criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant-induced suicidality? Clinical Trials 6 2009 109 118 43
46. I.M. Wiborg, and A.A. Dahl Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Archives of General Psychiatry 53 1996 689 694
47. D. Westen, and K. Morrison A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies Journal of Consulting and Clinical Psychology 69 2001 875 899
48. M. Zimmerman, I. Chelminski, and M.A. Posternak Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial American Journal of Psychiatry 162 2005 1370 1372
49. M. Zimmerman, J.I. Mattia, and M.A. Posternak Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? American Journal of Psychiatry 159 2002 469 473
50. C.M. Zitrin, D.F. Klein, and M.G. Woerner Treatment of agoraphobia with group exposure in vivo and imipramine Archives of General Psychiatry 37 1980 63 72
51. C.M. Zitrin, D.F. Klein, M.G. Woerner, and D.C. Ross Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo Archives of General Psychiatry 40 1983 125 138